André Pfob

Physician-Scientist focusing on #AI and #breastcancer @uniklinik_hd | HSO2 Fellow Digital Oncology | Lancet Commission Cancer & Health Systems

[Peter Dubsky @breastDoktor]

1/5 Practice-changing at #ASCO26: the PREPEC trial (OPBC-02), presented by Walter Weber — the first international phase III RCT comparing pre- vs sub-pectoral implant breast reconstruction . 383 pts, 26 centers, 10 countries. #bcsm

[Felicia Knaul @FeliciaKnaul]

We took advantage of being together at #ASCO2026 for a meeting of the Lancet Commission on Cancer and Health Systems. Great to connect in person and advance our shared work! We missed our colleagues Mary Gospodarowicz, C.S. Pramesh, Patricia Garcia and Bev Essue. Looking forward to the full team being together soon.

Tuvimos la oportunidad de reunirnos con miembros de la Comisión Lancet sobre Cáncer y Sistemas de Salud durante #ASCO2026. ¡Fue un gusto conectar en persona y seguir avanzando en nuestro trabajo conjunto! Extrañamos a nuestros colegas Mary Gospodarowicz, C.S. Pramesh, Patricia Garcia y Bev Essue, y esperamos que todo el equipo pueda reunirse pronto.

#ASCO2026 #LancetCommission #HealthSystems #GlobalHealth #UHC #HealthEquity @TheLancet @WisdomVania @jrgralow @renu_nargund @andrepfob @Dilyara_Kaidar @lsaulsbe @mtkutluk

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Lymph node surgery and CDK4/6 inhibitors in early breast cancer: A cost-consequence analysis from 5 randomized trials
✨Rapid Oral Session 1
@andrepfob #ESMOBreast26 @OncoAlert #OncoAlertAF
🔗 https://t.co/6LTIFNwtvg

[Yakup Ergün @dr_yakupergun]

Axillary surgery → CDK4/6 eligibility: what’s the real gain?

🔍5 RCTs, n=19,541
➡️Patients needed to prevent 1 event:
→ iDFS: 106–123
→ DDFS: 119–129
→ OS: 345–807

CDK4/6 benefit exists, but:
→ Grade ≥3 AEs: ~50–60%
→ ↑ Lymphedema: +3.9% (SLNB), +10.6% (cALND)

💬Using axillary surgery solely to guide CDK4/6 therapy → high NNT, added morbidity, marginal OS gain

https://t.co/PvOVn2VDSX

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials
🔗 https://t.co/6LTIFNwtvg
@OncoAlert #OncoAlertAF @TheLancetOncol @andrepfob

[Europa Donna @EuropaDonnaEUR]

At #EBCC15, the first ED session explored how AI is already shaping breast cancer care and what still needs to be addressed. From screening to research, AI shows real impact. But one message stood out:
“AI is only as good as the data behind it.” Human oversight remains essential.

[Lie Cai @liecaii]

@Abdominal_Rad @RadGeek @LetDdiceFlyHigh @ClinMedJournals @SocietyAbdRad Honored to be selected as one of the Pinnacle Papers in 2025 published on @Abdominal_Rad we summarized the application of artificial intelligence in abdominal and pelvic ultrasound. https://t.co/Vr7TUgc9p7 @andrepfob

[The Lancet Oncology @TheLancetOncol]

🎧Listen to our Dec podcast with @breastDoktor and @andrepfob discussing the Lucerne Toolbox 3 (📑https://t.co/gOsH7QSSit), digital health and AI in early breast cancer

Spotify: https://t.co/ODNEz8V87P

Apple: https://t.co/0B0UdUOYli

[The ASCO Post @ASCOPost]

AI-guided shear wave elastography model showed similar accuracy to expert readings of B-mode ultrasound for diagnosis of BI-RADS 3/4 masses #BreastCancer
🔸 Significantly reduced false positives (20.4% vs 53.8%; P < .001)

From Lie Cai, MD; @DrGolatta

https://t.co/ID3yeirCly

[Mirrors of Medicine @mirrorsmed]

Deep Learning Model for Breast Shear Wave Elastography to Improve #BreastCancer Diagnosis (INSPiRED 006)

https://t.co/ztrp8KEbYH

This international, multicenter study evaluated a deep learning model trained on shear wave elastography (SWE) images (AI-SWE) to improve diagnosis of BI-RADS 3 and 4 breast masses. Using data from over 1,200 patients across 12 sites, the model achieved high accuracy (AUROC ~0.93–0.94) in two external validation cohorts, including data from newer SWE software. Compared with B-mode ultrasound alone, AI-SWE maintained equivalent sensitivity (~98%) but reduced false positives by up to 62%, suggesting a potential role in lowering unnecessary biopsies.

These findings support AI-SWE as a promising tool to complement breast cancer diagnostics, warranting further integration into clinical workflows.

@OncoAlert 🚨
@liecaii
@andrepfob
@drcgibbons
@DrGolatta

[OncoAlert @OncoAlert]

Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006)

https://t.co/xTXodIlfRN

This study evaluated the use of a deep learning model applied to shear wave elastography (AI-SWE) for improving the diagnosis of BI-RADS 3 and 4 breast masses. Using data from an international multicenter trial across 12 institutions, the model was trained on 4,026 images from 924 patients and externally validated on two independent cohorts. AI-SWE achieved high diagnostic accuracy with AUROCs of 0.94 and 0.93, matching the sensitivity of B-mode ultrasound while significantly reducing false-positive rates by 38–62%, potentially decreasing unnecessary biopsies.

These findings suggest that AI-SWE could complement existing imaging methods, and further research should assess its role in multimodal #BreastCancer diagnostics.

@liecaii
@andrepfob
@drcgibbons
@DrGolatta

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

@matteolambe @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @raalbany @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @itrisabel

[SABCS @SABCSSanAntonio]

Do All Early-stage Breast Cancer Patients Need Axillary Staging?
Melissa Pilewskie and Peter Dubsky will debate this question in a special session at #SABCS25 (December 9-12). Learn more:
https://t.co/sQsYeB7ocV
@breastDoktor

[Peter Dubsky @breastDoktor]

Imagine you could have a validated test that can identify patients with very low DR rates in a high-risk, MonarchE type of population. Free access to this incredible biomarker work led bei Curie and IGR ! #bcsm Journal of Clinical Oncology https://t.co/DFvdaokmQo

[André Pfob @andrepfob]

7/ Presented at #ESMOBreast25 @myESMO. Thank you @ErikaHamilton9 for selecting this as oral presentation. @PTarantinoMD @pinkerdk @breastDoktor @RitseMann

[André Pfob @andrepfob]

1/ 🚨 New in Journal of Clinical Oncology @JCO_ASCO @ASCO
We built and validated the largest model for AI-enhanced shear wave elastography (AI-SWE) in breast cancer.
👉 https://t.co/m5gDwMSyiH
With @liecaii @DrCGibbons @andrepfob
#AIinMedicine #BreastCancer

[André Pfob @andrepfob]

6/ What’s new with AI-SWE?
✔️ Evaluates the whole lesion, not just a cutoff.
✔️ Maintains sensitivity (~98%).
✔️ Cuts false positives (38–62%).
✔️ Works across multiple centers & software versions.

From Breast Center Heidelberg to the world 🌍

[André Pfob @andrepfob]

1/ 🚨 New in Journal of Clinical Oncology @JCO_ASCO @ASCO
We built and validated the largest model for AI-enhanced shear wave elastography (AI-SWE) in breast cancer.
👉 https://t.co/m5gDwMSyiH
With @liecaii @DrCGibbons @andrepfob
#AIinMedicine #BreastCancer

[Journal of Clinical Oncology @JCO_ASCO]

Deep Learning Model for Breast Shear Wave Elastography to Improve #BreastCancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. Co-authored by @andrepfob, @liecaii, @drcgibbons, et al.

Read the full article. https://t.co/53c8kajKzn
#bcsm